SecBot SecBot
Biotech Drug Report Generated Jul 13, 2026

Jemperli

GSK·GSK plc
NEUTRAL
Drug Impact Rating5/10
Trial phase
Approved (Phase 3 / registrational Phase 2 for additional indications)
Time to market
Already marketed (first FDA approval April 2021). Potential label expansion in dMMR/MSI-H rectal cancer would follow AZUR-1 data (H2 2026) and subsequent BLA filing.
Why 5/10
Jemperli is already FDA-approved and generating >$1B in run-rate revenue, so there is no PDUFA binary. The next hard dated catalyst is the AZUR-1 registrational Phase 2 readout in dMMR/MSI-H rectal cancer, expected H2 2026. At a ~$52B market cap diversified pharma like GSK (~$34B revenue), even a strong readout moves the stock a modest 2-4%. Score capped at 5 per the rubric for approved drugs with no pending regulatory decision.
Actionable Insight NEUTRAL

Watch for AZUR-1 Phase 2 registrational data in H2 2026, a positive readout (extending the 100% cCR rate seen in the MSK-collaboration study) could lead to an FDA filing for rectal cancer and support the ~$2.5B+ peak sales consensus. Be aware of the AnaptysBio royalty dispute going to trial in July 2026, which could alter Jemperli's economics. For a diversified phyla stock like GSK, Jemperli is a growth driver in oncology but not a stand-alone thesis.

Price Chart

Loading chart...

Executive Summary

Jemperli (dostarlimab) is GSK's PD-1 checkpoint inhibitor immunotherapy, first approved by the FDA in April 2021 for dMMR endometrial cancer and expanded in August 2024 to cover all adult patients with primary advanced/recurrent endometrial cancer, including the MMRp/MSS tumors that represent ~75% of cases. It generated ~$785M in the first nine months of 2025 and is on track to exceed $1B in annual sales, with consensus peak sales above $2.5B by 2030. The drug faces intense competition from Merck's Keytruda and AstraZeneca's Imfinzi, and GSK has suffered setbacks in ovarian cancer and NSCLC trials. The next major catalyst is the AZUR-1 Phase 2 registrational readout in dMMR/MSI-H rectal cancer (H2 2026), where an earlier MSK-collaboration study showed an unprecedented 100% clinical complete response rate. A concurrent royalty dispute with AnaptysBio (trial set for July 2026) adds headline risk.

How It Works

Jemperli is an immunotherapy, a lab-made antibody that blocks a protein called PD-1 on immune cells (T-cells). PD-1 normally acts as an "off switch" that cancer cells flip to avoid being attacked. By blocking that switch, Jemperli keeps the immune system active against cancer cells. It is in the same class as Merck's Keytruda and Bristol Myers' Opdivo.

Trial Status

Jemperli is commercially approved in the US and EU for endometrial cancer (multiple lines). The registrational Phase 2 AZUR-1 trial (dMMR/MSI-H rectal cancer) is fully enrolled with data expected H2 2026. Phase 3 AZUR-2 (colon cancer) and JADE (head & neck cancer) trials are ongoing (readouts H2 2028). The Phase 3 RUBY trial in endometrial cancer met its dual primary endpoints with statistically significant OS benefit. The Phase 3 FIRST trial in ovarian cancer and ZEAL-1L in NSCLC missed primary endpoints.

The Two-Sided Case

▲ Bull Case5
Only PD-1/PD-L1 inhibitor to show a statistically significant overall survival benefit in the frontline all-comer endometrial cancer setting, 31% reduction in risk of death vs chemo alone (RUBY Part 1 trial, 44.6 vs 28.2 months median OS).
AZUR-1 registrational data in dMMR/MSI-H rectal cancer (expected H2 2026) builds on an MSK-collaboration study showing 100% clinical complete response, potentially practice-changing if validated, opening a new indication with breakthrough therapy designation.
Commercial momentum is strong: Q3 2025 sales of $303M (+17% QoQ), YTD 2025 ~$785M; Q1 2026 oncology segment up 23% YoY (£512M). Consensus peak sales forecast ~$2.5B+ by 2030.
August 2024 FDA label expansion to all-comer endometrial cancer (including MMRp/MSS) dramatically expanded the addressable patient population, MMRp/MSS represents ~75% of endometrial cancer cases.
European Commission expanded approval in January 2025 to include all adult patients with primary advanced/recurrent endometrial cancer.
▼ Bear Case5
Intense competition: Keytruda (Merck) and Imfinzi (AstraZeneca) are also approved in endometrial cancer, and Keytruda remains the dominant PD-1 franchise across multiple tumor types with vastly more commercial infrastructure.
Phase 3 FIRST/ENGOT-OV44 trial in ovarian cancer failed to show overall survival benefit for Jemperli + Zejula, mirroring Keytruda's failure in the same setting, suggesting PD-1 inhibition may not work in ovarian cancer.
Phase 3 ZEAL-1L trial in first-line NSCLC did not meet its primary PFS endpoint, curtailing a major market opportunity.
Active litigation: GSK's Tesaro unit is in a legal dispute with AnaptysBio over Jemperli royalty obligations. A Delaware court denied GSK's attempt to slash royalties by 50%, and a trial set for July 2026 could upend the economic terms or even threaten licensing rights.
As a PD-1 inhibitor entering a crowded market, Jemperli remains a latecomer behind Keytruda, which has near-universal oncology prescriber mindshare and vastly more approved indications.

Upcoming Catalysts

  • AZUR-1 registrational Phase 2 pivotal data readout in dMMR/MSI-H rectal cancer, expected H2 2026.
  • AnaptysBio royalty dispute trial, scheduled July 14, 2026 (Delaware Chancery Court).
  • AZUR-2 Phase 3 colon cancer data, expected H2 2028.
  • Potential FDA BLA submission for rectal cancer label expansion (contingent on AZUR-1 data).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report

Sources · 12

Hover a chip for the title
1 en.wikipedia.org2 fda.gov3 fda.gov4 us.gsk.com5 gsk.com6 gsk.com7 clinicaltrialsarena.com8 precisionmedicineonline.com9 fiercepharma.com10 jamessharp.co.uk11 gsk.com12 drugs.com